Document Detail


Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients.
MedLine Citation:
PMID:  11267858     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Colorectal cancer is one of the most common tumour types with approximately one third of the tumours located within the rectum. Rectal cancer differs somewhat from colon cancer, e.g. regarding the method of operation and the use of preoperative radiotherapy due to a tendency for local tumour recurrence. Proteolytic enzymes have been identified as key molecules in tumour invasion and metastasis, and factors within the urokinase-plasminogen activation (uPA) system have been associated with prognosis in several tumour types, including colorectal cancer. Recently, methods have been developed to analyse the soluble fraction of the plasminogen activator receptor (suPAR) in blood samples. An association between elevated suPAR levels and poor prognosis has recently been demonstrated in colorectal cancer. We have measured suPAR levels in pretreatment plasma samples from 173 rectal cancer patients in order to confirm its prognostic strength in this clinical entity. suPAR levels were determined in ethylenediamine tetraacetic acid (EDTA) plasma by a kinetic enzyme-linked immunosorbent assay (ELISA) and analysed with respect to sex, age, Dukes' stage, tumour differentiation grade and survival. In a univariate analysis, continuous suPAR plasma levels were associated with survival (P<0.001) with shorter survival among patients with high suPAR values. Patients with suPAR values within the upper quartile had significantly shorter survival (hazard ratio (HR) 2.2, 95% confidence interval (CI) 1.3-43.7, P=0.002). In a multivariate Cox analysis, increasing suPAR values predicted shorter survival independent from Dukes' stage and tumour differentiation grade with an adjusted HR of 2.2 per ng/ml suPAR (95% CI 1.2-4.0, P=0.01). This study thus confirms that measurement of suPAR in preoperative plasma samples gives independent prognostic information in rectal cancer patients, higher values being associated with shorter survival.
Authors:
E Fernebro; R R Madsen; M Fernö; N Brünner; P Bendahl; I J Christensen; A Johnson; M Nilbert
Related Documents :
15019918 - Palliative therapy of rectal cancer. overview: epidemiology, indications, goals, extent...
6538498 - Cell cycle parameters and prognosis of colorectal cancer.
19641928 - Curved cutter stapler vs. linear stapler in rectal cancer surgery: a pilot prospective ...
21066978 - Quality assurance through outcome registration in colorectal cancer: an ecco initiative...
7902728 - Multidrug resistance: clinical relevance in acute leukemia.
21966988 - Quality of life in chinese home-based advanced cancer patients: does awareness of cance...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  37     ISSN:  0959-8049     ISO Abbreviation:  Eur. J. Cancer     Publication Date:  2001 Mar 
Date Detail:
Created Date:  2001-03-27     Completed Date:  2001-04-12     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  England    
Other Details:
Languages:  eng     Pagination:  486-91     Citation Subset:  IM    
Affiliation:
The Department of Oncology, The Jubileum Institution, University Hospital, S-221 85, Lund, Sweden. eva.fernebro@onk.lu.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Analysis of Variance
Enzyme-Linked Immunosorbent Assay
Female
Follow-Up Studies
Humans
Male
Middle Aged
Prognosis
Receptors, Cell Surface / blood*
Receptors, Urokinase Plasminogen Activator
Rectal Neoplasms / blood,  diagnosis*
Retrospective Studies
Survival Analysis
Tumor Markers, Biological / blood
Chemical
Reg. No./Substance:
0/PLAUR protein, human; 0/Receptors, Cell Surface; 0/Receptors, Urokinase Plasminogen Activator; 0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and p...
Next Document:  A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particula...